CES1 Carriers in the PAPI Study

Exclusion Criteria

• •Currently pregnant or less than 6 months have passed since delivery
• •Currently breast feeding
• •Has a history of a bleeding disorder or major spontaneous bleed, such as peptic ulcer, epistasis, or intracranial bleed
• •Has severe hypertension, defined by a blood pressure above 160/95 mm Hg
• •Takes medications that would affect the outcome(s) to be measured and cannot willingly and safely, in the opinion of the treating physician and study physician, discontinue these medications for 1 week prior to protocol initiation
• •Is taking vitamins or other supplements and is unwilling to discontinue use for at least 1 week prior to study
• •Has a coexisting malignancy
• •Has a creatinine level greater than 2.0 mg/dl, aspartate transaminase (AST) or alanine transaminase (ALT) greater than two times the upper limit of normal, hematocrit less than 32%, or a thyroid-stimulating hormone (TSH) less than 0.4 or greater than 5.5 mIU/L
• •Has a bleeding disorder or history of gastrointestinal bleeding or other major bleeding episode
• •Is currently taking aspirin, clopidogrel, or anti-coagulants, such as warfarin, heparin, or GPIIb/IIIa antagonists, and have conditions that might place the participant at increased risk from withdrawal of these medications 14 days prior to protocol initiation
• •History of unstable angina, heart attack, angioplasty (including stent placement), coronary artery bypass surgery, atrial fibrillation, stroke or transient ischemic attacks, diabetes, or deep vein thrombosis or other thrombosis
• •Has polycythemia, or thrombocytosis, defined by a platelet count greater than 500,000
• •Has thrombocytopenia, defined by a platelet count less than 75,000
• •Has had surgery within the last 6 months
• •Has an aspirin or clopidogrel allergy